Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 5/20 | 0.76 |
| ▸ | FNTA | P49354 | 1/20 | 0.73 |
| ▸ | FNTB | P49356 | 1/20 | 0.73 |
| ▸ | CYP19A1 | P11511 | 11/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.43 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.43 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6303535 | 0.84 | FNTA (1.00) | CNR1FNTAFNTBCYP19A1CYP1A2 | |
| SCHEMBL5756709 | 0.79 | FNTA (0.70) | CNR1FNTAFNTBCYP19A1CYP1A2 | |
| SCHEMBL4156125 | 0.79 | FNTA (0.85) | CNR1FNTAFNTBCYP19A1CYP1A2 | |
| SCHEMBL6866443 | 0.78 | FNTA (0.88) | CNR1FNTAFNTBCYP19A1CYP3A4 | |
| SCHEMBL5781643 | 0.78 | RHEB (0.47) | CNR1FNTAFNTB | |
| SCHEMBL3217241 | 0.75 | MEN1 (0.60) | CYP1A2CYP3A4 | |
| SCHEMBL6872273 | 0.75 | FNTA (0.69) | CNR1FNTAFNTBCYP19A1CYP1A2 | |
| SCHEMBL6305490 | 0.75 | FNTA (0.81) | CNR1FNTAFNTBCYP19A1CYP3A4 | |
| SCHEMBL11366789 | 0.73 | CYP19A1 (1.00) | CNR1FNTAFNTBCYP19A1CYP1A2 | |
| SCHEMBL5561624 | 0.72 | FNTA (0.66) | CNR1FNTAFNTBCYP19A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7129356-B2 | Farnesyl transferase inhibiting 4-substituted quinoline and quinazoline derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-10-31 | — | — | US | disclosed |
| EP-1347966-B1 | FARNESYL TRANSFERASE INHIBITING 4-SUBSTITUTED QUINOLINE AND QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2006-03-08 | — | — | EP | disclosed |
| US-20040063944-A1 | Farnesyl transferase inhibiting 4-substituted quinoline and quinazoline derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-04-01 | — | — | US | disclosed |
| EP-1347966-A1 | FARNESYL TRANSFERASE INHIBITING 4-SUBSTITUTED QUINOLINE AND QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-10-01 | — | — | EP | disclosed |
| WO-2002051835-A1 | FARNESYL TRANSFERASE INHIBITING 4-SUBSTITUTED QUINOLINE AND QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063944-A1 | Farnesyl transferase inhibiting 4-substituted quinoline and quinazoline derivatives | FNTA, FNTB, CYP7A1 | CNR1 1830/4885FNTA 1/4885FNTB 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.